Recent News
Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-Oncology Therapies https://lnkd.in/dFmQQj6 Password: 5J#j3@B+
Read More...Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies In oncology, going beyond the current standard of […] Read More
NEW HAVEN, Conn., June 01, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, Inc., a leading company in the field of developing […] Read More
Synergistic Potential of Kleo’s Antibody Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of […] Read More
Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT New Haven, CT, May […] Read More
Events
